Kelly Warfield - Emergent Biosolutions Senior Development
| 0IGA Stock | 6.82 1.59 0.00% |
Executive
Kelly Warfield is Senior Development of Emergent Biosolutions
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Emergent Biosolutions Management Efficiency
The company has return on total asset (ROA) of (0.0422) % which means that it has lost $0.0422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3464) %, meaning that it generated substantial loss on money invested by shareholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| William Karlson | Air Products Chemicals | N/A | |
| Bettina Schafer | LPKF Laser Electronics | N/A | |
| William Pellicciotti | Air Products Chemicals | 44 | |
| Olle Glassel | Systemair AB | 58 | |
| Simon Moore | Air Products Chemicals | N/A | |
| ChengChiang Wang | Compal Electronics GDR | N/A | |
| Roger Dewing | Air Products Chemicals | N/A | |
| Evgeny An | Air Products Chemicals | N/A | |
| David Collins | Litigation Capital Management | N/A | |
| Kat Gieras | Litigation Capital Management | N/A | |
| Eduardo Villar | Hochschild Mining plc | 51 | |
| BjornOsvald Skandsen | Systemair AB | 51 | |
| Guo Yu | Compal Electronics GDR | N/A | |
| Geoff Achilles | Air Products Chemicals | N/A | |
| Walter Nelson | Air Products Chemicals | N/A | |
| JuiTsung Chen | Compal Electronics GDR | N/A | |
| Eduardo Noriega | Hochschild Mining plc | 38 | |
| Max Bottrill | Games Workshop Group | N/A | |
| Mudassar Ali | Systemair AB | N/A | |
| Siddharth Manjeshwar | Air Products Chemicals | N/A | |
| Matthew Denney | Litigation Capital Management | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jessica Perl, Corporate Counsel | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, General Affairs | ||
| Kelly Warfield, Senior Development | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, Vice Relations | ||
| Stephanie Duatschek, Chief VP | ||
| Katherine Strei, Ex Officer | ||
| Michelle Pepin, Senior Officer | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Haywood Miller, Interim Officer | ||
| Joseph Papa, CEO President | ||
| Atul Saran, Exec Officer | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Ex COO | ||
| Paul Williams, Senior Business | ||
| Richard Lindahl, CFO VP |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 1.06 B | ||||
| Shares Outstanding | 50.95 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 59.91 % | ||||
| Price To Sales | 0.39 X | ||||
| Revenue | 1.05 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.